Journal Article
. 2018 Aug; 27(3):1099-1108.
doi: 10.1007/s00520-018-4399-3.

Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study

Florence Van Ryckeghem 1 Chloë Haverbeke 2 Wim Wynendaele 3 Guy Jerusalem 4 Luc Somers 5 Anke Van den Broeck 6 Sofie Vingerhoedt 6 Simon Van Belle 7 
Affiliations
  • PMID: 30099601
  •     33 References
  •     2 citations

Abstract

Purpose: To prevent febrile neutropenia (FN), European Organisation for Research and Treatment of Cancer (EORTC) guidelines recommend primary prophylaxis with granulocyte colony-stimulating factors (PPG) for patients at high risk (≥ 20%) of FN. In Belgium, the use of PPG is restricted by specific reimbursement criteria. The impact of these criteria on PPG use and adherence to guidelines is unknown.

Methods: This multicentre, cross-sectional, observational study aimed to describe PPG use by FN risk category in breast cancer patients who were scheduled to receive myelosuppressive chemotherapy in outpatient clinics in Belgium during a 2-week period between 13 October and 12 December 2014.

Results: In total, 490 patients were enrolled. Median age was 57.0 years. Based on their chemotherapy regimen, 53.9, 5.1 and 41.0% of patients were at a low, intermediate and high risk of FN, respectively. Overall, 39.8% of patients received PPG (17.0, 12.0 and 73.1% of those receiving low-, intermediate- and high-risk regimens, respectively). In the high-risk category, PPG was used in 89.9% of dose-dense and in 25.0% of classical chemotherapy regimens. PPG use was adherent to EORTC guidelines in 75.3% of patients (30.6% appropriate use, 44.7% appropriate non-use). EORTC guidelines would recommend PPG use in 46.1% of this study population (n = 226), and its use was reimbursable in Belgium in 76.1% of these patients (n = 172), but only 66.4% of them received PPG (n = 150).

Conclusions: Both Belgian reimbursement criteria and physician decision-making led to a proportion of patients for whom PPG treatment was recommended but finally not receiving it.

Keywords: Breast cancer; Chemotherapy; Febrile neutropenia; Granulocyte colony-stimulating factor; Prophylaxis.

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.
F A Holmes, J A O'Shaughnessy, +10 authors, B C Liang.
J Clin Oncol, 2002 Feb 01; 20(3). PMID: 11821454
A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
M D Green, H Koelbl, +12 authors, International Pegfilgrastim 749 Study Group.
Ann Oncol, 2002 Dec 19; 14(1). PMID: 12488289
Highly Cited.
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
Jeffrey Crawford, David C Dale, Gary H Lyman.
Cancer, 2004 Jan 13; 100(2). PMID: 14716755
Highly Cited. Review.
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
Charles L Vogel, Marek Z Wojtukiewicz, +5 authors, Lee S Schwartzberg.
J Clin Oncol, 2005 Feb 19; 23(6). PMID: 15718314
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2005 May 17; 365(9472). PMID: 15894097
Highly Cited.
Optimizing adjuvant chemotherapy in early-stage breast cancer.
Edith Perez, Hyman B Muss.
Oncology (Williston Park), 2006 Mar 02; 19(14). PMID: 16506631
Review.
Impact of effective prevention and management of febrile neutropenia.
D Krell, A L Jones.
Br J Cancer, 2009 Sep 17; 101 Suppl 1. PMID: 19756004    Free PMC article.
The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
Laetitia Gerlier, Mark Lamotte, +11 authors, Luc Somers.
BMC Cancer, 2010 Nov 26; 10. PMID: 21092320    Free PMC article.
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
M S Aapro, J Bohlius, +10 authors, European Organisation for Research and Treatment of Cancer.
Eur J Cancer, 2010 Nov 26; 47(1). PMID: 21095116
Highly Cited. Systematic Review.
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres.
Y Madarnas, S F Dent, +5 authors, T Vandenberg.
Curr Oncol, 2011 Jun 10; 18(3). PMID: 21655158    Free PMC article.
Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.
Arnold L Potosky, Jennifer L Malin, +4 authors, Jane C Weeks.
J Natl Cancer Inst, 2011 Jun 15; 103(12). PMID: 21670423    Free PMC article.
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), R Peto, +15 authors, K Pritchard.
Lancet, 2011 Dec 14; 379(9814). PMID: 22152853    Free PMC article.
Highly Cited.
The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.
Antonio Salar, Corinne Haioun, +9 authors, Pieternella J Lugtenburg.
Leuk Res, 2012 Mar 06; 36(5). PMID: 22385870
Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF).
Arash Naeim, Henry J Henk, +4 authors, Robert Deeter.
BMC Cancer, 2013 Jan 10; 13. PMID: 23298389    Free PMC article.
Pegfilgrastim prophylaxis in patients at different levels of risk for chemotherapy-associated febrile neutropenia: an observational study.
Michael Fiegl, Günther G Steger, +3 authors, Wolfgang Willenbacher.
Curr Med Res Opin, 2013 Mar 01; 29(5). PMID: 23444969
Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practice.
K Krzemieniecki, P Sevelda, +7 authors, J Maenpaa.
Support Care Cancer, 2013 Oct 25; 22(3). PMID: 24154740    Free PMC article.
Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy.
Mi Rim Choi, Craig A Solid, +4 authors, Thomas J Arneson.
Support Care Cancer, 2014 Feb 05; 22(6). PMID: 24492928
Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
Hazem Assi, Joshua Murray, Laura Boyle, Daniel Rayson.
Support Care Cancer, 2014 Jul 06; 22(12). PMID: 24996828
G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.
Gisoo Barnes, Ashutosh Pathak, Lee Schwartzberg.
Cancer Med, 2014 Nov 21; 3(6). PMID: 25410813    Free PMC article.
Review.
Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.
Yoshimasa Kosaka, Yoshiaki Rai, +7 authors, Kazuo Tamura.
Support Care Cancer, 2015 Jan 13; 23(4). PMID: 25576433    Free PMC article.
Emergency room visits and hospital admission rates after curative chemotherapy for breast cancer.
Natalia M Pittman, Wilma M Hopman, Mihaela Mates.
J Oncol Pract, 2015 Jan 15; 11(2). PMID: 25585617
The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.
Li Wang, Onur Baser, +2 authors, Richard Barron.
Support Care Cancer, 2015 Mar 31; 23(11). PMID: 25821144    Free PMC article.
Systematic Review.
Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials.
Fausto Petrelli, Mary Cabiddu, +4 authors, Sandro Barni.
Breast Cancer Res Treat, 2015 Apr 29; 151(2). PMID: 25917869
Systematic Review.
Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.
Hartmut Link, J Nietsch, +2 authors, Supportive Care Group (ASORS) of the German Cancer Society (DKG).
Support Care Cancer, 2015 Jun 18; 24(1). PMID: 26081593
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
E Senkus, S Kyriakides, +6 authors, ESMO Guidelines Committee.
Ann Oncol, 2015 Sep 01; 26 Suppl 5. PMID: 26314782
Highly Cited.
Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.
Gilles Freyer, Ewa Kalinka-Warzocha, +9 authors, Zsolt Szabo.
Med Oncol, 2015 Sep 01; 32(10). PMID: 26315712
The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
Tran Do, Rohan Medhekar, +3 authors, Meghana V Trivedi.
Breast Cancer Res Treat, 2015 Sep 05; 153(3). PMID: 26337685
Review.
Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
Lindsey Robert Baden, Sankar Swaminathan, +22 authors, Courtney Smith.
J Natl Compr Canc Netw, 2016 Jul 14; 14(7). PMID: 27407129
Highly Cited.
Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.
S Redana, A Sharp, +4 authors, A Ring.
Breast, 2016 Aug 30; 30. PMID: 27569021
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.
J Klastersky, J de Naurois, +5 authors, ESMO Guidelines Committee.
Ann Oncol, 2016 Sep 25; 27(suppl 5). PMID: 27664247
Highly Cited.
Recommendations for the Use of White Blood Cell Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
Thomas J Smith, Kari Bohlke, James O Armitage.
J Oncol Pract, 2015 Nov 01; 11(6). PMID: 29424584
Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.
C L Bennett, T J Smith, +6 authors, R J Winn.
J Clin Oncol, 1996 Sep 01; 14(9). PMID: 8823330
Healthcare providers' adherence to breast cancer guidelines in Europe: a systematic literature review.
Ena Niño de Guzmán, Yang Song, +10 authors, Ignacio Ricci-Cabello.
Breast Cancer Res Treat, 2020 May 08; 181(3). PMID: 32378052    Free PMC article.
Systematic Review.
A questionnaire survey on evaluation for penetration and compliance of the Japanese Guideline on Febrile Neutropenia among hematology-oncology physicians and surgeons.
Nobu Akiyama, Takuho Okamura, +12 authors, Sadamoto Zenda.
Support Care Cancer, 2021 May 20;. PMID: 34008079